Sorafenib in Myelodysplastic Syndrome
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy of sorafenib in patients with Myelodysplastic Syndrome (MDS). Eligible subjects will receive Sorafenib administered at 400mg orally twice a day, given on days 1-28 of a 28-day cycle. Patients will be evaluated for hematological response after 2 cycles and then every 3 cycles thereafter for a maximum of 5 years from study entry. If a patient achieves a complete response they may receive an additional 6 cycles of therapy beyond documentation of complete response unless unacceptable toxicity occurs. For patients with partial response, hematological improvement or stable disease they will continue treatment until relapse, progression of disease, or unacceptable toxicity occurs.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: all patients sorafenib |
Drug: Sorafenib
400 mg twice a day until progression or unacceptable toxicity develops.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Subjects Achieving Hematological Response [During treatment - up to a maximum of 5 years]
Hematological response is defined as the number of subjects who achieve either a complete response (CR), Partial response (PR) or Hematologic improvement.(HI). HI is defined as peripheral blood counts with hemoglobin ≥11 g/dL, absolute neutrophil count ≥1x10(9)/L and platelet count ≥100x10(9)/L, and normal bone marrow morphology with no evidence of dysplasia or blasts. CR is defined as the disappearance of all signs and symptoms related to disease, along with HI. PR is defined as fulfilling the criteria for CR in the peripheral blood but blasts decreasing by 50% or more in the bone marrow or to a less advanced WHO classification pretreatment.
Secondary Outcome Measures
- Number of Subjects Requiring Dose Reductions [While on study drug, a maximum of 5 years]
The number of subjects who took study drug for more than 1 cycle and required a dose reduction down to the next dose level.
- Time to Progression [5 years]
Time to progression will be defined as the number of months between on-study and the date of progression or death, whichever comes first, in subjects who took study drug for at least cycle 1.
- Overall Survival [1 year from the last dose of study drug]
Overall Survival is defined as the number of months from enrollment onto the study until death from any cause in subjects who took study drug for at least cycle 1.
- Change in Microvessel Density [Measured before and after treatment]
Microvessel density will be measured before and after treatment, and the distribution of change across time will be summarized with descriptive statistics.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have a diagnosis of primary or therapy-related myelodysplastic syndrome or myelodysplastic/ myeloproliferative disorders as defined by the WHO
-
Refractory anemia with excess blasts - 1 or 2
-
Chronic myelomonocytic leukemia type 2
-
Refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia with ringed sideroblasts, 5q- syndrome, myelodysplastic syndrome unclassified or chronic myelomonocytic leukemia type 1 if at least one of the following criteria is met: HgB < 10 g/dl, Platelets < 50,000/ul,ANC < 1,000 ul, Transfusion dependent defined as 2 transfusions within an 8 week period.
-
Patients may have low, intermediate-1, intermediate-2 or high risk MDS or CMML.
-
Patients are eligible without regard to prior treatment status except for allogenic bone marrow transplant.
-
Patients must be 18 years of age or older.
-
Patient has an estimated or measured creatinine clearance ≥30 ml/min at study enrollment.
-
AST, ALT, total bilirubin ≤ than 2.5 times the upper limit of normal.
-
ECOG performance status of 0-2.
-
Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
-
Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.
-
Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 2 weeks after study completion.
Exclusion Criteria:
-
Female subject is pregnant or lactating. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result within 2 weeks of enrollment. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
-
Patient has received other investigational drugs for this disease within 14 days of enrollment
-
No growth factor support with erythropoietin, GCSF, or GMCSF within 28 days of enrolling in the study.
-
Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
-
Patients with another malignancy within the last one year (from documentation of remission) other than basal or squamous cell skin cancer or CIS of the cervix.
-
Patients who underwent allogeneic stem cell transplant will be excluded.
-
History of leukemia (having more than 20% blasts in blood or marrow)
-
Current treatment with coumadin, heparin and its derivatives.
-
Major surgery (including needle biopsy of visceral organs) for 1-month prior to study and fully recovered. In addition, no placement of a subcutaneous or tunneled venous access device for 3 days prior to study and adequately healed.
-
Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NHYA class ≥ 2), uncontrolled cardiac arrhythmias, and disseminated intravascular coagulation.
-
No use of hematopoetic growth factors within 4 weeks of starting sorafenib.
-
Known severe hypersensitivity to Sorafenib or any component of the formulation.
-
Caution should be exercised with the concomitant use of other CYP3A4 inducers, such as rifampin, St. John's Wort, phenytoin, phenobarbital and dexamethasone.
-
Uncontrolled hypertension with a systolic blood pressure greater than 160 or a diastolic blood pressure greater than 100 despite treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
Sponsors and Collaborators
- Duke University
- Bayer
Investigators
- Principal Investigator: David A Rizzieri, MD, Duke University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00008151
Study Results
Participant Flow
| Recruitment Details | Patients 18 years or older with an ECOG performance status of 0-2, and adequate renal and hepatic function with a diagnosis of primary or therapy-related MDS were eligible for this study. Patients were enrolled from 2006 to 2011 at Duke and Duke Oncology Network sites. The study was closed prematurely due to poor response and patient withdrawals. |
|---|---|
| Pre-assignment Detail | Three patients were ineligible due to the presence of AML in the BM done at the time of screening. |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | All patients who signed consent |
| Period Title: Overall Study | |
| STARTED | 19 |
| Started Study Drug | 16 |
| COMPLETED | 7 |
| NOT COMPLETED | 12 |
Baseline Characteristics
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | All patients who signed consent |
| Overall Participants | 19 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
4
21.1%
|
| >=65 years |
15
78.9%
|
| Sex: Female, Male (Count of Participants) | |
| Female |
6
31.6%
|
| Male |
13
68.4%
|
| Region of Enrollment (participants) [Number] | |
| United States |
19
100%
|
Outcome Measures
| Title | Number of Subjects Achieving Hematological Response |
|---|---|
| Description | Hematological response is defined as the number of subjects who achieve either a complete response (CR), Partial response (PR) or Hematologic improvement.(HI). HI is defined as peripheral blood counts with hemoglobin ≥11 g/dL, absolute neutrophil count ≥1x10(9)/L and platelet count ≥100x10(9)/L, and normal bone marrow morphology with no evidence of dysplasia or blasts. CR is defined as the disappearance of all signs and symptoms related to disease, along with HI. PR is defined as fulfilling the criteria for CR in the peripheral blood but blasts decreasing by 50% or more in the bone marrow or to a less advanced WHO classification pretreatment. |
| Time Frame | During treatment - up to a maximum of 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| There were 16 subjects enrolled in the trial. 9 subjects refused further bone marrow biopsy to assess response to therapy. Therefore, there were 7 evaluable subjects. One subject experienced PR |
| Arm/Group Title | Evaluable Subjects |
|---|---|
| Arm/Group Description | Patients who received at least one cycle of study drug and underwent bone marrow assessments |
| Measure Participants | 7 |
| Partial Response |
1
5.3%
|
| Complete Response |
0
0%
|
| Hematologic Improvement |
0
0%
|
| Title | Number of Subjects Requiring Dose Reductions |
|---|---|
| Description | The number of subjects who took study drug for more than 1 cycle and required a dose reduction down to the next dose level. |
| Time Frame | While on study drug, a maximum of 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| 7 Subjects completed beyond cycle 1. 4 of those subjects had dose reductions during the time they took study drug. |
| Arm/Group Title | Evaluable Subjects |
|---|---|
| Arm/Group Description | Patients who received at least one cycle of study drug and underwent bone marrow assessments |
| Measure Participants | 7 |
| Number [participants] |
4
21.1%
|
| Title | Time to Progression |
|---|---|
| Description | Time to progression will be defined as the number of months between on-study and the date of progression or death, whichever comes first, in subjects who took study drug for at least cycle 1. |
| Time Frame | 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| 7 patients completed cycle one and had bone marrow biopsies to confirm response. |
| Arm/Group Title | Evaluable Subjects |
|---|---|
| Arm/Group Description | Patients who received at least one cycle of study drug and underwent bone marrow assessments |
| Measure Participants | 7 |
| Median (Full Range) [months] |
3.5
|
| Title | Overall Survival |
|---|---|
| Description | Overall Survival is defined as the number of months from enrollment onto the study until death from any cause in subjects who took study drug for at least cycle 1. |
| Time Frame | 1 year from the last dose of study drug |
Outcome Measure Data
| Analysis Population Description |
|---|
| 7 subjects completed cycle 1 or beyond. |
| Arm/Group Title | Evaluable Patients |
|---|---|
| Arm/Group Description | Patients who received at least one cycle of study drug and underwent bone marrow assessments |
| Measure Participants | 7 |
| Mean (Full Range) [months] |
15
|
| Title | Change in Microvessel Density |
|---|---|
| Description | Microvessel density will be measured before and after treatment, and the distribution of change across time will be summarized with descriptive statistics. |
| Time Frame | Measured before and after treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| This outcome was not analysed due to the early closure of the study. |
| Arm/Group Title | Evaluable Subjects |
|---|---|
| Arm/Group Description | Patients who received at least one cycle of study drug and underwent bone marrow assessments |
| Measure Participants | 0 |
Adverse Events
| Time Frame | 30 days after the last dose of study drug | |
|---|---|---|
| Adverse Event Reporting Description | Serious Adverse Events/Other Adverse events are recorded whether or not they are thought to be related to the study drug. SAEs are listed for all patients who took at least one dose of study drug. Due to early study closure and patient withdrawals, Other AEs are listed for 9 patients only. | |
| Arm/Group Title | All Patients | |
| Arm/Group Description | SAEs are listed for all patients who took at least one dose of study drug. Due to early study closure and patient withdrawals, Other AEs are listed for 9 patients only. | |
All Cause Mortality |
||
| All Patients | ||
| Affected / at Risk (%) | # Events | |
| Total | / (NaN) | |
Serious Adverse Events |
||
| All Patients | ||
| Affected / at Risk (%) | # Events | |
| Total | 5/16 (31.3%) | |
| Blood and lymphatic system disorders | ||
| Hemoglobin | 1/16 (6.3%) | 1 |
| Cardiac disorders | ||
| hypotension | 1/16 (6.3%) | 1 |
| atrial fibrillation | 1/16 (6.3%) | 1 |
| Gastrointestinal disorders | ||
| Mucositis | 1/16 (6.3%) | 1 |
| small bowel obstruction | 1/16 (6.3%) | 1 |
| Infections and infestations | ||
| Myositis | 1/16 (6.3%) | 1 |
| Febrile Neutropenia | 1/16 (6.3%) | 1 |
| Nervous system disorders | ||
| syncope | 1/16 (6.3%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| All Patients | ||
| Affected / at Risk (%) | # Events | |
| Total | 9/9 (100%) | |
| Blood and lymphatic system disorders | ||
| Hemoglobin | 3/9 (33.3%) | 3 |
| Eye disorders | ||
| Ocular / Visual - Other | 1/9 (11.1%) | 1 |
| Blurred vision | 1/9 (11.1%) | 1 |
| Gastrointestinal disorders | ||
| Constipation | 3/9 (33.3%) | 4 |
| Diarrhea | 5/9 (55.6%) | 7 |
| Dysphagia (difficulty swallowing) | 1/9 (11.1%) | 1 |
| Esophagitis | 1/9 (11.1%) | 1 |
| Hemorrhage, GI - Anus | 1/9 (11.1%) | 1 |
| Mucositis / stomatitis | 3/9 (33.3%) | 3 |
| Nausea | 3/9 (33.3%) | 6 |
| Obstruction, GI - Small bowel NOS | 1/9 (11.1%) | 1 |
| Pain - Abdomen | 2/9 (22.2%) | 2 |
| Vomiting | 2/9 (22.2%) | 3 |
| General disorders | ||
| Fatigue (asthenia, lethargy, malaise) | 5/9 (55.6%) | 11 |
| Fever (in the absence of neutropenia) | 1/9 (11.1%) | 1 |
| Pain - Chest / thorax NOS | 2/9 (22.2%) | 2 |
| Pain - Other | 2/9 (22.2%) | 3 |
| Rigors / chills | 1/9 (11.1%) | 1 |
| Infections and infestations | ||
| Infection - Lung (pneumonia) | 1/9 (11.1%) | 1 |
| Infection with unknown ANC - Mucosa | 1/9 (11.1%) | 1 |
| Injury, poisoning and procedural complications | ||
| Bruising | 1/9 (11.1%) | 1 |
| Investigations | ||
| ALT, SGPT (serum glutamic pyruvic transaminase) | 3/9 (33.3%) | 4 |
| AST, SGOT (serum glutamic oxaloacetic transaminase) | 2/9 (22.2%) | 3 |
| Bilirubin (hyperbilirubinemia) | 1/9 (11.1%) | 1 |
| Creatinine | 1/9 (11.1%) | 1 |
| Metabolic / Laboratory - Other | 1/9 (11.1%) | 1 |
| Platelets | 1/9 (11.1%) | 1 |
| Weight loss | 2/9 (22.2%) | 3 |
| Metabolism and nutrition disorders | ||
| Albumin, serum-low (hypoalbuminemia) | 1/9 (11.1%) | 2 |
| Anorexia | 3/9 (33.3%) | 5 |
| Calcium, serum-low (hypocalcemia) | 1/9 (11.1%) | 1 |
| Glucose, serum-low (hypoglycemia) | 1/9 (11.1%) | 1 |
| Sodium, serum-low (hyponatremia) | 1/9 (11.1%) | 1 |
| Musculoskeletal and connective tissue disorders | ||
| Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-lower | 1/9 (11.1%) | 1 |
| Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body / generalized | 2/9 (22.2%) | 2 |
| Musculoskeletal / Soft Tissue - Other | 2/9 (22.2%) | 2 |
| Myositis (inflammation / damage of muscle) | 1/9 (11.1%) | 1 |
| Pain - Extremity-limb | 1/9 (11.1%) | 2 |
| Nervous system disorders | ||
| Dizziness | 3/9 (33.3%) | 4 |
| Neurology - Other | 1/9 (11.1%) | 1 |
| Pain - Head / headache | 2/9 (22.2%) | 2 |
| Psychiatric disorders | ||
| Insomnia | 1/9 (11.1%) | 1 |
| Mood Alteration - Anxiety | 1/9 (11.1%) | 1 |
| Mood Alteration - Depression | 1/9 (11.1%) | 1 |
| Renal and urinary disorders | ||
| Renal / Genitourinary - Other | 1/9 (11.1%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Dyspnea (shortness of breath) | 4/9 (44.4%) | 5 |
| Hemorrhage, pulmonary / upper respiratory - Respiratory tract NOS | 1/9 (11.1%) | 1 |
| Hypoxia | 1/9 (11.1%) | 1 |
| Pain - Throat / pharynx / larynx | 1/9 (11.1%) | 1 |
| Skin and subcutaneous tissue disorders | ||
| Dry Skin | 3/9 (33.3%) | 3 |
| Hair Loss / Alopecia (scalp or body) | 2/9 (22.2%) | 2 |
| Pruritus / itching | 1/9 (11.1%) | 1 |
| Rash / desquamation | 3/9 (33.3%) | 4 |
| Sweating (diaphoresis) | 1/9 (11.1%) | 1 |
| Vascular disorders | ||
| Hypertension | 2/9 (22.2%) | 2 |
| Hypotension | 2/9 (22.2%) | 2 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | David Rizzieri, MD |
|---|---|
| Organization | Duke University Medical Center |
| Phone | 919-668-1014 |
| David.Rizzieri@duke.edu |
- Pro00008151